ADC Therapeutics SA (ADCT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 30M 60M 90M Q3 '21: 13.1M Q4 '21: 17M Q1 '22: 46.5M Q2 '22: 17.3M Q3 '22: 76.3M Q4 '22: 69.8M Q1 '23: 19M Q2 '23: 19.3M Q3 '23: 14.5M Q4 '23: 16.8M Q1 '24: 18.1M Q2 '24: 17.4M Q3 '24: 18.5M Q4 '24: 16.9M Q1 '25: 23M Q2 '25: 18.8M Q3 '25: 16.4M Q4 '25: 23.1M Q1 '26: 20.9M Q2 '26: 19.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -57.8M Q4 '21: -62.8M Q1 '22: -40.4M Q2 '22: -69.4M Q3 '22: -3.1M Q4 '22: -10.7M Q1 '23: -50.2M Q2 '23: -39.6M Q3 '23: -36.1M Q4 '23: -40M Q1 '24: -33.6M Q2 '24: -29M Q3 '24: -35.6M Q4 '24: -32.4M Q1 '25: -28.5M Q2 '25: -44.1M Q3 '25: -31M Q4 '25: -17.9M Q1 '26: -25.2M Q2 '26: -25.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -71.5M Q4 '21: -34.4M Q1 '22: -16.7M Q2 '22: -64.4M Q3 '22: -50.6M Q4 '22: -24.2M Q1 '23: -59.4M Q2 '23: -48.9M Q3 '23: -46.7M Q4 '23: -85M Q1 '24: -46.6M Q2 '24: -36.5M Q3 '24: -44M Q4 '24: -30.7M Q1 '25: -38.6M Q2 '25: -56.6M Q3 '25: -41M Q4 '25: -6.4M Q1 '26: -33M Q2 '26: -16.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 800K 1.6M 2.4M Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 121K Q3 '21: 502K Q4 '21: 770K Q1 '22: 529K Q2 '22: 2.3M Q3 '22: 1.3M Q4 '22: 489K Q1 '23: 590K Q2 '23: 1.3M Q3 '23: 366K Q4 '23: 254K Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -58.6M Q4 '21: -61.6M Q1 '22: -33.9M Q2 '22: -53M Q3 '22: 2.2M Q4 '22: -52.1M Q1 '23: -15.4M Q2 '23: -35M Q3 '23: -36.7M Q4 '23: -31.6M Q1 '24: -44.1M Q2 '24: -32.8M Q3 '24: -25M Q4 '24: -21.9M Q1 '25: -56.3M Q2 '25: -24.1M Q3 '25: -29.6M Q4 '25: -31.1M Q1 '26: -29.7M Q2 '26: -11.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -60M Q4 '21: -62.1M Q1 '22: -34.1M Q2 '22: -53.1M Q3 '22: 2M Q4 '22: -52.2M Q1 '23: -16.4M Q2 '23: -36.2M Q3 '23: -37.3M Q4 '23: -32M Q1 '24: -44.6M Q2 '24: -32.9M Q3 '24: -25.3M Q4 '24: -21.9M Q1 '25: -56.6M Q2 '25: -24.1M Q3 '25: -29.6M Q4 '25: -31.1M Q1 '26: -29.7M Q2 '26: -11.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q1 '20: 51M Q2 '20: 62.9M Q3 '20: 70.9M Q1 '21: 76.7M Q2 '21: 76.7M Q3 '21: 76.7M Q1 '22: 76.8M Q2 '22: 76.9M Q3 '22: 78.4M Q1 '23: 80.8M Q2 '23: 81.5M Q3 '23: 82.3M Q1 '24: 82.6M Q2 '24: 95.7M Q3 '24: 104.8M Q1 '25: 107.2M Q2 '25: 113.7M Q3 '25: 136.4M Q1 '26: 154.1M Q2 '26: 155M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q4 '22: -2.01 Q1 '23: -2.52 Q2 '23: -2.28 Q3 '23: -2.20 Q4 '23: -2.94 Q1 '24: -2.77 Q2 '24: -2.55 Q3 '24: -2.40 Q4 '24: -1.63 Q1 '25: -1.43 Q2 '25: -1.55 Q3 '25: -1.43 Q4 '25: -1.14 Q1 '26: -0.99 Q2 '26: -0.60 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.